KR870007938A - 세팔로스포린 화합물의 제조방법 - Google Patents

세팔로스포린 화합물의 제조방법 Download PDF

Info

Publication number
KR870007938A
KR870007938A KR870001745A KR870001745A KR870007938A KR 870007938 A KR870007938 A KR 870007938A KR 870001745 A KR870001745 A KR 870001745A KR 870001745 A KR870001745 A KR 870001745A KR 870007938 A KR870007938 A KR 870007938A
Authority
KR
South Korea
Prior art keywords
formula
compound
salt
producing
group
Prior art date
Application number
KR870001745A
Other languages
English (en)
Other versions
KR930007808B1 (ko
Inventor
겐쪼 나이또
유끼오 이시바시
Original Assignee
우메모또 요시마사
다께다 야꾸힌 고오교 가부시끼 가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 우메모또 요시마사, 다께다 야꾸힌 고오교 가부시끼 가이샤 filed Critical 우메모또 요시마사
Publication of KR870007938A publication Critical patent/KR870007938A/ko
Application granted granted Critical
Publication of KR930007808B1 publication Critical patent/KR930007808B1/ko

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D501/00Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/207-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D501/00Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/02Preparation
    • C07D501/04Preparation from compounds already containing the ring or condensed ring systems, e.g. by dehydrogenation of the ring, by introduction, elimination or modification of substituents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D501/00Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/187-Aminocephalosporanic or substituted 7-aminocephalosporanic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D501/00Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/207-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/247-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/38Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof
    • C07D501/46Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof with the 7-amino radical acylated by carboxylic acids containing hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

내용 없음

Description

세팔로스포린 화합물의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (7)

  1. 하기 일반식 (Ⅱ)의 화합물 또는 그의 염을 친핵성 화합물 또는 그의 염 및 하기 일반식 (Ⅲ)의 화합물과 반용시킴을 특징으로 하는 하기 일반식 (Ⅰ)의 세팔로스포린 화합물 또는 그의 염의 제조 방법;
    [식중, R은 수소원자, 아실기 또는 아실기가 아닌 다른 보호기를 의미하고, Q는 수소원자 또는 에스테르 잔기를 의미하며, Y는 친핵성 화합물의 잔기를 의미하고, 점선은 세펨고리의 2- 또는 3-위치에 이중결합이 있음을 나타내며, 및 R1,R2및 R3는 각각 8 이하의 탄소원자를 갖는 탄화수소기를 의미하거나, 또는 R1과 R2,과 R1또는 R3와 R2는 결합하여 폴리메틸기를 형성할 수도 있다.]
  2. 제 1 항에 있어서, 식중 R1,R2및 R3가 각각 C1∼8알킬기인 일반식(Ⅰ)의 세팔로스포린 화합물 또는 그염의 제조 방법
  3. 제 1 항에 있어서, 식중 일반식화합물이 트리메틸 포스파이트, 트리에틸포스파이트, 트리이소프로 필포스파이트, 또는 트리-n-부틸 포스파이트인 일반식 (Ⅰ)의 세팔로스포린 화합물 또는 그 염의 제조 방법.
  4. 제 1 항에 있어서, 식중 점선은 세펨고리의 3-위치에 이중 결합이 있음을 나타내는 일반식 (Ⅰ)의 세팔로스포린 화합물 또는 그 염의 제조 방법.
  5. 제 1 항에 있어서, 식중 친핵성 화합물이 질소 친핵성 화합물인 일반식 (Ⅰ)의 세팔로스포린 화합물 또는 그 염의 제조 방법.
  6. 제 1 항에 있어서, 식중 친핵성 화합물이 황 친핵성 화합물인 일반식 (Ⅰ)의 세팔로스포린 화합물 또는 그 염의 제조 방법.
  7. 제 1 항에 있어서, 식중 R로 나타내는 아실기가 하기 일반식 (Ⅳ)인 일반식 (Ⅰ)의 세팔로스포린 화합물 또는 그 염의 제조 방법.
    [식중, RZ-락탐 및 펩티드 합성분야에서 아미노기 보호의 목적으로 통상적으로 사용되는 아미노-보호기로 보호시킬 수도 있는 아미노기이다.]
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019870001745A 1986-02-28 1987-02-27 세팔로스포린 화합물의 제조방법 KR930007808B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP44992 1986-02-28
JP4499286 1986-02-28

Publications (2)

Publication Number Publication Date
KR870007938A true KR870007938A (ko) 1987-09-23
KR930007808B1 KR930007808B1 (ko) 1993-08-20

Family

ID=12706934

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019870001745A KR930007808B1 (ko) 1986-02-28 1987-02-27 세팔로스포린 화합물의 제조방법

Country Status (10)

Country Link
US (1) US4980464A (ko)
EP (1) EP0234549B1 (ko)
JP (1) JPH082908B2 (ko)
KR (1) KR930007808B1 (ko)
CN (1) CN1024011C (ko)
AT (1) ATE83486T1 (ko)
CA (1) CA1293718C (ko)
DE (1) DE3783048T2 (ko)
ES (1) ES2052501T3 (ko)
HU (1) HU198499B (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587474A (en) * 1992-06-18 1996-12-24 Tanabe Seiyaku Co., Ltd. Method for removing the protecting group for carboxyl group
AU2004248138B2 (en) * 2003-05-29 2009-09-03 The Scripps Research Institute Targeted delivery to legumain-expressing cells
CN101374856A (zh) * 2005-11-29 2009-02-25 斯克里普斯研究学院 抑制肿瘤细胞浸润、转移和血管生成
US8198434B2 (en) 2008-05-07 2012-06-12 Idexx Laboratories, Inc. Process for preparing cefsulodin sodium
CN110950816B (zh) * 2019-12-13 2021-07-06 山东金城医药化工有限公司 1-(2-二甲基氨基乙基)-5-巯基四唑的合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0135683B1 (en) * 1981-09-10 1987-07-22 Takeda Chemical Industries, Ltd. Method for production of cephalosporin compounds
DE3789412T2 (de) * 1986-10-02 1994-06-30 Asahi Chemical Ind Verfahren zur Herstellung von 3-Alkoxymethylcephalosporinen.

Also Published As

Publication number Publication date
ES2052501T3 (es) 1994-07-16
EP0234549B1 (en) 1992-12-16
KR930007808B1 (ko) 1993-08-20
HUT44560A (en) 1988-03-28
CN1024011C (zh) 1994-03-16
CA1293718C (en) 1991-12-31
DE3783048T2 (de) 1993-04-15
CN87101581A (zh) 1987-09-30
JPH082908B2 (ja) 1996-01-17
HU198499B (en) 1989-10-30
DE3783048D1 (de) 1993-01-28
ATE83486T1 (de) 1993-01-15
EP0234549A2 (en) 1987-09-02
JPS62277389A (ja) 1987-12-02
EP0234549A3 (en) 1989-05-31
US4980464A (en) 1990-12-25

Similar Documents

Publication Publication Date Title
KR870008889A (ko) 베타-락탐화합물, 및 그의 제조 방법
KR840001156A (ko) 벤지미다졸 유도체의 제조방법
KR840000563A (ko) 세펨 화합물의 제조방법
KR850001905A (ko) 벤조시클로 알칸 유도체의 제조방법
KR870007938A (ko) 세팔로스포린 화합물의 제조방법
NO173554C (no) Additivblanding, spesielt for motorbrensel, motorbrensel, anvendelse av additivblandinger
KR850002274A (ko) 지방산 유도체의 제조방법
KR840006482A (ko) 디히드로피라졸로 [3,4-b]피리딘 유도체의 제조방법
KR910005859A (ko) 항종양제
KR920004392A (ko) 플루오로에틸캄프토테신 유도체
KR830010106A (ko) 피페라진 유도체의 제조방법
KR850008173A (ko) 세팔로 스포린 및 그의 제조 중간체의 제조방법
KR860003272A (ko) 펩타이드-치환된-헤테로사이클릭 화합물의 제조방법
CA2093510A1 (en) Oxysulfonyl carbamates
KR850002987A (ko) 2-아자사이클로알킬티오페넴 유도체의 제조방법
KR840005455A (ko) 세팔로스포린 유도체류의 제조방법
KR840001578A (ko) 9,10-치환된 2-메시틸이미노-3-알킬-3,4,6,7-테트라하이드로-2H-피리미도(6,1-a)이소퀴놀린-4-온의 제조방법
KR840000578A (ko) 포스포리피드 유도체의 제조방법
KR840001154A (ko) 1,2-디티올-3-일리덴 암모늄 유도체의 제조방법
KR870002118A (ko) 벤질아민 유도체 및 그 제조방법
KR840008004A (ko) 트로폰 유도체의 제조방법
KR870003114A (ko) 테트라하이드로이소퀴놀린 유도체
KR900007776A (ko) 나프탈렌 유도체의 제조방법
KR830006173A (ko) 3-아미노-1, 2-프로판디올 유도체의 제조방법
KR850008659A (ko) 테트라히드로나프탈레놀 유도체의 제조방법

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20000811

Year of fee payment: 8

LAPS Lapse due to unpaid annual fee